Ashahikawa, Japan

  • Featured

    Integument-1 study

    The study drug consists of a cream of the medication or a placebo (same cream without the active drug) that will be applied once daily for 28 days. This treatment is experimental, and you (or your child) will have 1 in 2 chances to be part of the placebo part of the study. At the end of the study, participants may be eligible to participate in the open-labeled study, which would allow the participants to continue to receive the study treatment. More information will be made available to the participants should they be interested. Blood samples will be collected on screening, day 1 and week 4. If you consent to medical photography, it will be performed at day 1, week 1 and week 4. For more information and to register to the study, please visit the study page: http://eczema-study.com/

    Phase

    3

    Span

    Sponsor

    Arcutis

    East Windsor, New Jersey

    Recruiting

  • Dupixent and Narrowband UVB for Atopic Dermatitis

    24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.

    Phase

    4

    Span

    139 weeks

    Sponsor

    Psoriasis Treatment Center of Central New Jersey

    East Windsor, New Jersey

    Recruiting

  • An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients

    30 subjects will be treated with increasing doses of Narrowband Ultraviolet phototherapy three times weekly for 12 weeks. Patients will then be evaluated every 6 weeks through week 36 to determine maintenance of response.

    Phase

    N/A

    Span

    113 weeks

    Sponsor

    Psoriasis Treatment Center of Central New Jersey

    East Windsor, New Jersey

    Recruiting

  • A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

    TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies. The duration of follow-up for participants enrolled in the EU is limited to 5-years. Those within in US and Canada may consent to indefinite follow-up.

    Phase

    N/A

    Span

    1672 weeks

    Sponsor

    Target PharmaSolutions, Inc.

    East Windsor, New Jersey

    Recruiting

  • Taltz in Combination With Enstilar for Psoriasis

    A single center study of 25 subjects to assess the addition of Enstilar Foam in patients receiving Taltz for ≥ 24 weeks with BSA between 3% and 8%.

    Phase

    4

    Span

    48 weeks

    Sponsor

    Psoriasis Treatment Center of Central New Jersey

    East Windsor, New Jersey

    Recruiting

  • ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.

    25 adult subjects with moderate to severe plaque psoriasis will receive Ilumya 100mg subcutaneously at weeks 0, 4 and 16. At week 16, patients with remaining BSA ˃3% will be given HALOG ointment 0.1% to apply BID for 4 weeks. Patients who have ≤3% BSA at week 16 will remain on Ilumya monotherapy. Patients will continue to be evaluated at weeks 20 and 24.

    Phase

    4

    Span

    47 weeks

    Sponsor

    Psoriasis Treatment Center of Central New Jersey

    East Windsor, New Jersey

    Recruiting

  • Duobrii in Combination With Biologics

    A single center, pilot study of 25 subjects to assess 12 weeks DUOBRII to patients with 2%-10% body surface area who are receiving biologic therapy for at least 24 weeks

    Phase

    4

    Span

    47 weeks

    Sponsor

    Psoriasis Treatment Center of Central New Jersey

    East Windsor, New Jersey

    Recruiting

  • Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis

    30 subjects treated with etanercept or adalimumab for at least 24 weeks with a body surface area 2-10% and physician global assessment greater than or equal to 2 will receive Enstilar® once daily for 4 weeks followed by QOD for 12 weeks.

    Phase

    4

    Span

    48 weeks

    Sponsor

    Psoriasis Treatment Center of Central New Jersey

    East Windsor, New Jersey

    Recruiting

  • Cryotherapy in Combination with Red Light PDT for Actinic Keratosis of Full Face

    Phase

    4

    Span

    113 weeks

    Sponsor

    Psoriasis Treatment Center of Central New Jersey

    East Windsor, New Jersey

    Recruiting

  • Upadacitinib for Prurigo Nodularis

    Phase

    4

    Span

    95 weeks

    Sponsor

    Psoriasis Treatment Center of Central New Jersey

    East Windsor, New Jersey

    Recruiting

1-10 of 16